Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Bicycle Therapeutics (BCYC) over the last 8 years, with Dec 2024 value amounting to $879.5 million.

  • Bicycle Therapeutics' Cash & Equivalents fell 27.22% to $648.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648.3 million, marking a year-over-year decrease of 27.22%. This contributed to the annual value of $879.5 million for FY2024, which is 67.07% up from last year.
  • According to the latest figures from FY2024, Bicycle Therapeutics' Cash & Equivalents is $879.5 million, which was up 67.07% from $526.4 million recorded in FY2023.
  • Bicycle Therapeutics' Cash & Equivalents' 5-year high stood at $879.5 million during FY2024, with a 5-year trough of $136.0 million in FY2020.
  • Over the past 3 years, Bicycle Therapeutics' median Cash & Equivalents value was $526.4 million (recorded in 2023), while the average stood at $581.7 million.
  • In the last 5 years, Bicycle Therapeutics' Cash & Equivalents spiked by 222.58% in 2021 and then dropped by 22.69% in 2022.
  • Bicycle Therapeutics' Cash & Equivalents (Yearly) stood at $136.0 million in 2020, then skyrocketed by 222.58% to $438.7 million in 2021, then dropped by 22.69% to $339.2 million in 2022, then spiked by 55.22% to $526.4 million in 2023, then spiked by 67.07% to $879.5 million in 2024.